Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue ...

Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ...

The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...

Exact Sciences (NASDAQ:EXAS) said it has secured exclusive rights to both current and future iterations of Freenome’s ...

Exact Sciences is laying off 4% of its overall workforce, including 80 positions at the headquarters in Madison.

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

Brisbane, California Friday, August 8, 2025, 10:00 Hrs [IST] ...

Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

Roivant Sciences has received a total of 2 ratings from analysts, with the consensus rating as Buy. With an average one-year ...